Meriwether Wealth & Planning LLC Takes Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Meriwether Wealth & Planning LLC purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the fourth quarter, Holdings Channel reports. The firm purchased 1,029 shares of the medical equipment provider’s stock, valued at approximately $537,000.

A number of other large investors have also added to or reduced their stakes in ISRG. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical during the fourth quarter worth approximately $26,000. BankPlus Trust Department acquired a new stake in Intuitive Surgical during the fourth quarter worth approximately $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Intuitive Surgical during the fourth quarter worth approximately $31,000. MidAtlantic Capital Management Inc. acquired a new stake in Intuitive Surgical during the third quarter worth approximately $33,000. Finally, Decker Retirement Planning Inc. acquired a new stake in Intuitive Surgical during the fourth quarter worth approximately $36,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 3.8 %

Shares of NASDAQ:ISRG opened at $518.26 on Monday. The firm has a market cap of $184.59 billion, a P/E ratio of 80.85, a P/E/G ratio of 5.85 and a beta of 1.43. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00. The business has a fifty day simple moving average of $571.36 and a 200 day simple moving average of $531.85.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ISRG shares. UBS Group increased their price target on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Citigroup upped their target price on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Barclays upped their target price on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. CICC Research started coverage on Intuitive Surgical in a research note on Monday, January 27th. They set a “neutral” rating and a $550.00 target price for the company. Finally, Truist Financial upped their target price on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Insider Buying and Selling

In other Intuitive Surgical news, CFO Jamie Samath sold 270 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50. Following the completion of the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at approximately $4,730,093.55. This trade represents a 2.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mark Brosius sold 489 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $533.18, for a total value of $260,725.02. Following the sale, the senior vice president now owns 2,091 shares of the company’s stock, valued at approximately $1,114,879.38. The trade was a 18.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,579 shares of company stock valued at $7,756,844 in the last three months. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.